Transmission-blocking vaccine of vivax malaria

Parasitology International

Volumn 52, Issue 1, 2003, Pages 1-11

  Tsuboi, Takafumi ^a   Tachibana, Mayumi ^a   Kaneko, Osamu ^a   Torii, Motomi ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Malaria; Plasmodium falciparum; Plasmodium vivax; Polymorphism; Transmission blocking vaccine

Indexed keywords

ANTIGEN; MALARIA VACCINE; RECOMBINANT PROTEIN;

AMINO ACID SUBSTITUTION; ANTIBODY RESPONSE; CHIMPANZEE; GENETIC POLYMORPHISM; MALARIA; MOLECULAR CLONING; MOSQUITO; NONHUMAN; OOCYST; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

ANIMALS; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; CELLS, CULTURED; MALARIA VACCINES; MALARIA, VIVAX; MODELS, BIOLOGICAL; PLASMODIUM VIVAX; RECOMBINANT PROTEINS;

PAN TROGLODYTES; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 0037350969     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5769(02)00037-5     Document Type: Review

References (69)

1. WHO. World malaria situation in 1994: WHO, 1997.
2. Breman J.G. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64:2001;1-11.
3. Mendis K., Sina B.J., Marchesini P., Carter R. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64:2001;97-106.
4. Kaslow D.C. Transmission-blocking vaccines. Hoffman S.L. Malaria vaccine development: a multi-immune response approach. 1996;181-227 ASM Press, Washington, DC.
5. Kaslow D.C. Transmission-blocking vaccines: uses and current status of development. Int. J. Parasitol. 27:1997;183-189.
6. Carter R. Transmission blocking malaria vaccines. Vaccine. 19:2001;2309-2314.
7. Kaneko A., Taleo G., Kalkoa M., Yamar S., Kobayakawa T., Bjorkman A. Malaria eradication on islands. Lancet. 356:2000;1560-1564.
8. Smith T.A., Leuenberger R., Lengeler C. Child mortality and malaria transmission intensity in Africa. Trends Parasitol. 17:2001;145-149.
9. Saul A. Minimal efficacy requirements for malarial vaccines to significantly lower transmission in epidemic or seasonal malaria. Acta Trop. 52:1993;283-296.
10. WHO. Malaria transmission-blocking vaccines: an ideal public good. WHO document no. (TDR/RBM/MAL/VAC/2000.1) available from WHO, Geneva, and on website available from http://www.who.int/tdr 2000.
11. Carter R., Mendis K.N., Roberts D. Spatial targeting of interventions against malaria. Bull. WHO. 78:2000;1401-1411.
12. Gwadz R.W. Successful immunization against the sexual stages of Plasmodium gallinaceum. Science. 193:1976;1150-1151.
13. Carter R., Chen D.H. Malaria transmission blocked by immunisation with gametes of the malaria parasite. Nature. 263:1976;57-60.
14. Gwadz R.W., Green I. Malaria immunization in Rhesus monkeys. A vaccine effective against both the sexual and asexual stages of Plasmodium knowlesi. J. Exp. Med. 148:1978;1311-1323.
15. Mendis K.N., Targett G.A. Immunisation against gametes and asexual erythrocytic stages of a rodent malaria parasite. Nature. 277:1979;389-391.
16. Templeton T.J., Kaslow D.C. Identification of additional members define a Plasmodium falciparum gene superfamily which includes Pfs48/45 and Pfs230. Mol. Biochem. Parasitol. 101:1999;223-227.
17. Kocken C.H., Jansen J., Kaan A.M., et al. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum. Mol. Biochem. Parasitol. 61:1993;59-68.
18. van Dijk M.R., Janse C.J., Thompson J., et al. A central role for P48/45 in malaria parasite male gamete fertility. Cell. 104:2001;153-164.
19. Williamson K.C., Criscio M.D., Kaslow D.C. Cloning and expression of the gene for Plasmodium falciparum transmission-blocking target antigen, Pfs230. Mol. Biochem. Parasitol. 58:1993;355-358.
20. Carter R., Graves P.M., Keister D.B., Quakyi I.A. Properties of epitopes of Pfs48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol. 12:1990;587-603.
21. Read D., Lensen A.H., Begarnie S., Haley S., Raza A., Carter R. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol. 16:1994;511-519.
22. Rener J., Graves P.M., Carter R., Williams J.L., Burkot T.R. Target antigens of transmission-blocking immunity on gametes of Plasmodium falciparum. J. Exp. Med. 158:1983;976-981.
23. Vermeulen A.N., Ponnudurai T., Beckers P.J., Verhave J.P., Smits M.A., Meuwissen J.H. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J. Exp. Med. 162:1985;1460-1476.
24. Carter R., Kumar N., Quakyi I., et al. Immunity to sexual stages of malaria parasites. Prog. Allergy. 41:1988;193-214.
25. Quakyi I.A., Carter R., Rener J., Kumar N., Good M.F., Miller L.H. The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies. J. Immunol. 139:1987;4213-4217.
26. Williamson K.C., Keister D.B., Muratova O., Kaslow D.C. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol. Biochem. Parasitol. 75:1995;33-42.
27. Grotendorst C.A., Kumar N., Carter R., Kaushal D.C. A surface protein expressed during the transformation of zygotes of Plasmodium gallinaceum is a target of transmission-blocking antibodies. Infect. Immun. 45:1984;775-777.
28. Tomas A.M., Margos G., Dimopoulos G., et al. Sinden RE. P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions. Embo. J. 20:2001;3975-3983.
29. Kaslow D.C., Quakyi I.A., Syin C., et al. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature. 333:1988;74-76.
30. Kaslow D.C., Syin C., McCutchan T.F., Miller L.H. Comparison of the primary structure of the 25 kDa ookinete surface antigens of Plasmodium falciparum and Plasmodium gallinaceum reveal six conserved regions. Mol. Biochem. Parasitol. 33:1989;283-287.
31. Duffy P.E., Pimenta P., Kaslow D.C. Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies. J. Exp. Med. 177:1993;505-510.
32. Paton M.G., Barker G.C., Matsuoka H., et al. Structure and expression of a post-transcriptionally regulated malaria gene encoding a surface protein from the sexual stages of Plasmodium berghei. Mol. Biochem. Parasitol. 59:1993;263-275.
33. Duffy P.E., Kaslow D.C. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect. Immun. 65:1997;1109-1113.
34. Tsuboi T., Cao Y.-M., Kaslow D.C., Shiwaku K., Torii M. Primary structure of a novel ookinete surface protein from Plasmodium berghei. Mol. Biochem. Parasitol. 85:1997;131-134.
35. Tsuboi T., Kaslow D.C., Cao Y.M., Shiwaku K., Torii M. Comparison of Plasmodium yoelii ookinete surface antigens with human and avian malaria parasite homologues reveals two highly conserved regions. Mol. Biochem. Parasitol. 87:1997;107-111.
36. Tsuboi T., Kaslow D.C., Gozar M.M., Tachibana M., Cao Y.M., Torii M. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Med. 4:1998;772-782.
37. Tachibana M., Tsuboi T., Templeton T.J., Kaneko O., Torii M. Presence of three distinct ookinete surface protein genes, Pos25, Pos28-1, and Pos28-2, in Plasmodium ovale. Mol. Biochem. Parasitol. 113:2001;341-344.
38. Kumar N., Carter R. Biosynthesis of two stage-specific membrane proteins during transformation of Plasmodium gallinaceum zygotes into ookinetes. Mol. Biochem. Parasitol. 14:1985;127-139.
39. Kaslow D.C., Bathurst I.C., Lensen T., Ponnudurai T., Barr P.J., Keister D.B. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect. Immun. 62:1994;5576-5580.
40. Tsuboi T., Cao Y.M., Hitsumoto Y., Yanagi T., Kanbara H., Torii M. Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity. Infect. Immun. 65:1997;2260-2264.
41. Kaslow D.C., Quakyi I.A., Keister D.B. Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum. Mol. Biochem. Parasitol. 32:1989;101-103.
42. Shi Y.P., Alpers M.P., Povoa M.M., Lal A.A. Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum. Mol. Biochem. Parasitol. 50:1992;179-180.
43. Hafalla J.C., Santiago M.L., Pasay M.C., et al. Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Mol. Biochem. Parasitol. 87:1997;97-99.
44. Quakyi I.A., Otoo L.N., Pombo D., et al. Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens. Am. J. Trop. Med. Hyg. 41:1989;125-134.
45. Carter R., Graves P.M., Quakyi I.A., Good M.F. Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies. J. Exp. Med. 169:1989;135-147.
46. Kaslow D.C., Shiloach J. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Biotechnology (NY). 12:1994;494-499.
47. Gozar M.M., Price V.L., Kaslow D.C. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect. Immun. 66:1998;59-64.
48. Lobo C.A., Dhar R., Kumar N. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect. Immun. 67:1999;1688-1693.
49. Shahabuddin M., Toyoshima T., Aikawa M., Kaslow D.C. Transmission-blocking activity of a chitinase inhibitor and activation of malarial parasite chitinase by mosquito protease. Proc. Natl. Acad. Sci. USA. 90:1993;4266-4270.
50. Vinetz J.M., Dave S.K., Specht C.A., et al. The chitinase PfCHT1 from the human malaria parasite Plasmodium falciparum lacks proenzyme and chitin-binding domains and displays unique substrate preferences. Proc. Natl. Acad. Sci. USA. 96:1999;14061-14066.
51. Vinetz J.M., Valenzuela J.G., Specht C.A., et al. Chitinases of the avian malaria parasite Plasmodium gallinaceum, a class of enzymes necessary for parasite invasion of the mosquito midgut. J. Biol. Chem. 275:2000;10331-10341.
52. Tsai Y.L., Hayward R.E., Langer R.C., Fidock D.A., Vinetz J.M. Disruption of Plasmodium falciparum chitinase markedly impairs parasite invasion of mosquito midgut. Infect. Immun. 69:2001;4048-4054.
53. Langer R.C., Hayward R.E., Tsuboi T., Tachibana M., Torii M., Vinetz J.M. Micronemal transport of Plasmodium ookinete chitinases to the electron-dense area of the apical complex for extracellular secretion. Infect. Immun. 68:2000;6461-6465.
54. Dessens J.T., Beetsma A.L., Dimopoulos G., et al. CTRP is essential for mosquito infection by malaria ookinetes. Embo. J. 18:1999;6221-6227.
55. Yuda M., Sakaida H., Chinzei Y. Targeted disruption of the Plasmodium berghei CTRP gene reveals its essential role in malaria infection of the vector mosquito. J. Exp. Med. 190:1999;1711-1716.
56. Templeton T.J., Kaslow D.C., Fidock D.A. Developmental arrest of the human malaria parasite Plasmodium falciparum within the mosquito midgut via CTRP gene disruption. Mol. Microbiol. 36:2000;1-9.
57. Lal A.A., Patterson P.S., Sacci J.B., et al. Anti-mosquito midgut antibodies block development of Plasmodium falciparum and Plasmodium vivax in multiple species of Anopheles mosquitoes and reduce vector fecundity and survivorship. Proc. Natl. Acad. Sci. USA. 98:2001;5228-5233.
58. Golenda C.F., Li J., Rosenberg R. Continuous in vitro propagation of the malaria parasite Plasmodium vivax. Proc. Natl. Acad. Sci. USA. 94:1997;6786-6791.
59. Premawansa S., Peiris J.S., Perera K.L., Ariyaratne G., Carter R., Mendis K.N. Target antigens of transmission blocking immunity of Plasmodium vivax malaria. Characterization and polymorphism in natural parasite isolates. J. Immunol. 144:1990;4376-4383.
60. Snewin V.A., Premawansa S., Kapilananda G.M., et al. Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector. J. Exp. Med. 181:1995;357-362.
61. Hisaeda H., Stowers A.W., Tsuboi T., et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68:2000;6618-6623.
62. Peiris J.S., Premawansa S., Ranawaka M.B., et al. Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 39:1988;26-32.
63. Gamage-Mendis A.C., Rajakaruna J., Carter R., Mendis K.N. Transmission blocking immunity to human Plasmodium vivax malaria in an endemic population in Kataragama, Sri Lanka. Parasite Immunol. 14:1992;385-396.
64. Ramsey J.M., Salinas E., Rodriguez M.H. Acquired transmission-blocking immunity to Plasmodium vivax in a population of southern coastal Mexico. Am. J. Trop. Med. Hyg. 54:1996;458-463.
65. Qari S.H., Shi Y.P., Goldman I.F., Nahlen B.L., Tibayrenc M., Lal A.A. Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. Mol. Biochem. Parasitol. 92:1998;241-252.
66. Kaslow D.C. Acquired immunity to sexual stages. Sherman I.W. Malaria: parasite biology, pathogenesis, and protection. 1998;457-466 ASM Press, Washington, DC.
67. Chitarra V., Holm I., Bentley G.A., Petres S., Longacre S. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. Mol. Cell. 3:1999;457-464.
68. Taylor D., Cloonan N., Mann V., Cheng Q., Saul A. Sequence diversity in rodent malaria of the Pfs28 ookinete surface antigen homologs. Mol. Biochem. Parasitol. 110:2000;429-434.
69. Escalante A.A., Lal A.A., Ayala F.J. Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum. Genetics. 149:1998;189-202.